WEKO3
アイテム
64Cu-ATSM internal radiotherapy to treat tumors with bevacizumab-induced vascular decrease and hypoxia: Imaging analysis with dual-isotope simultaneous SPECT/PET/CT
https://repo.qst.go.jp/records/66870
https://repo.qst.go.jp/records/668708579758e-6bc3-4846-a2c9-3ea2371d018d
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2018-08-02 | |||||
| タイトル | ||||||
| タイトル | 64Cu-ATSM internal radiotherapy to treat tumors with bevacizumab-induced vascular decrease and hypoxia: Imaging analysis with dual-isotope simultaneous SPECT/PET/CT | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Yoshii, Yukie
× Yoshii, Yukie× Yoshimoto, Mitsuyoshi× Matsumoto, Hiroki× Furukawa, Takako× Zhang, Ming-Rong× Inubushi, Masayuki× Tsuji, Atsushi× Fujibayashi, Yasuhisa× Higashi, Tatsuya× Saga, Tsuneo× 吉井 幸恵× 吉本 光喜× 古川 高子× 張 明栄× 犬伏 正幸× 辻 厚至× 藤林 康久× 東 達也× 佐賀 恒夫 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, is an antiangiogenic agent clinically used for various cancers. However, repeated use of this agent leads to tumor-decreased vascularity and hypoxia, which results in drug delivery deficiency and induction of malignant behaviors in tumors. To address this, we focused on a theranostic agent, 64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM), which possesses high tissue permeability and can target the over-reduced state under hypoxia within tumors. The efficacy of internal radiotherapy with 64Cu-ATSM was examined in mice bearing tumors with bevacizumab-induced vascular decrease and hypoxia. Methods: Human colon carcinoma HT-29 tumor-bearing mice were treated with bevacizumab (5 mg/kg twice a week) for 3 weeks to produce a model for tumors with bevacizumab-induced vascular decrease and hypoxia. Characteristics within the bevacizumab-treated tumors were examined. Dual-isotope simultaneous SPECT/PET/CT imaging with a blood pool-detecting agent 99mTc-labeled human serum albumin and 64Cu-ATSM was performed. In vivo treatment study was then performed. Results: The bevacizumab-treated HT-29 tumors showed decreased blood vessel density, activation of the HIF-1 signaling pathway and upregulation of genes involved in this pathway, and increased uptake of 64Cu-ATSM, compared to the control. SPECT/PET/CT imaging showed reduced vascularity and increased proportion of hypoxic areas in the bevacizumab-treated tumors. 64Cu-ATSM therapy was effective to inhibit tumor growth and prolong survival in the bevacizumab-treated tumor-bearing mice without major adverse effects. Conclusion: 64Cu-ATSM therapy effectively enhanced anti-tumor effects in tumors with bevacizumab-induced vascular decrease and hypoxia. 64Cu-ATSM therapy could be an additional treatment to antiangiogenic therapy. | |||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 第12回日本分子イメージング学会学術集会 | |||||
| 発表年月日 | ||||||
| 日付 | 2017-05-26 | |||||
| 日付タイプ | Issued | |||||
